Rotavirus outer capsid glycoprotein VP7 (G2 genotype) (VP7 G2)

Rotavirus VP7 is a 37-kDa glycoprotein that constitutes the major component of the outer layer of the rotavirus triple-layered particle (UniProt: P04502). It is essential for viral infectivity, facilitating the attachment of the virus to host cell receptors and the subsequent penetration of the cell membrane (PubMed: 23713370). The G2 designation refers to a specific serotype/genotype of the VP7 protein, which is a frequent cause of diarrheal outbreaks globally (CDC: Rotavirus). Because VP7 contains the primary epitopes for neutralizing antibodies, it is a fundamental target for vaccine development. Current live-attenuated vaccines, such as the pentavalent RotaTeq, specifically incorporate the G2 antigen to elicit protective immunity against this strain (FDA: RotaTeq Label). Targeting VP7 effectively prevents the virus from initiating the replication cycle, thereby reducing the clinical severity of rotavirus-induced gastroenteritis (WHO: Rotavirus vaccines). The protein's structure is calcium-dependent, and its loss leads to the decapsidation of the virus, which is a key step in the viral life cycle. Monitoring the prevalence of G2 antigens is crucial for assessing vaccine efficacy and potential strain replacement in different geographic regions.

Other names

Outer capsid glycoprotein VP7G2 antigenGlycoprotein VP7VP7 proteinB-type antigen

Active immunization to induce neutralizing antibodies against the VP7 G2 antigen, preventing viral attachment and entry into host enterocytes.